4DMedical (ASX:4DX) said medical device firm Olympus launched its SeleCT Screening population-level emphysema screening program using the 4DMedical's lung density analysis technology, according to a Wednesday Australian bourse filing.
The solution reviews existing computed tomography (CT) scans to identify patients with advanced emphysema who may be candidates for bronchoscopic lung volume reduction.
The program established Olympus as a key partner and scaled 4DMedical's lung analysis technology across major US health systems, the filing added.
4DMedical's shares fell 3% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。